BITMEX
3.1.2022 08:02:07 CET | Business Wire | Press release
Crypto exchange BitMEX is pleased to welcome Rupertus Rothenhaeuser as its new Chief Commercial Officer (CCO). As CCO, Rupertus will spearhead BitMEX’s ‘Beyond Derivatives’ plan to expand into spot, brokerage, custody, information products, and establish BitMEX Academy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220102005033/en/
In particular he is responsible for developing the exchange’s global client relationships, overseeing the commercial success of its expanding range of products, and growing BitMEX’s market share in the hyper-competitive crypto space. Reporting directly to BitMEX’s CEO, Alexander Höptner, Rupertus started his new role on 1 January and will be based in Asia.
Rupertus previously served as CEO at Crypto Finance (Brokerage) AG for over a year, during which time he championed innovative digital asset services for the group’s banking clients. He has a strong, well-rounded track record from previous roles, having worked in leadership positions at ABN AMRO Bank, BNP Paribas, Macquarie Group, SIX Digital Exchange, Boerse Stuttgart, and other leading financial and fintech companies in London, Hong Kong, Paris, and Germany.
Rupertus said: “BitMEX has major expansion plans in the works, and I’m excited to have joined their growing team at this pivotal time. I see many opportunities for us to expand beyond derivatives, develop game-changing products, and offer significant value in the crypto space for retail and institutional clients alike. The next few years will bring explosive growth for this industry, and BitMEX will be at the forefront of this as we contribute to a better financial ecosystem for all users.”
BitMEX’s CEO, Alexander Höptner, said: “I’m thrilled to welcome Rupertus to our senior leadership team as we expand our services, reach new markets, and transform BitMEX from a derivatives-focused platform to a full crypto ecosystem. Our mission is to lead the digital financial revolution, and I am confident that Rupertus is uniquely suited to drive our commercial development.”
BitMEX is actively hiring to support its growing user base. Click here to explore open career opportunities at BitMEX.
About BitMEX
BitMEX is a trading platform that offers investors access to the global digital currency financial markets. BitMEX is owned by HDR Global Trading Limited. To learn more about BitMEX, our vision, growing team, and the road ahead, please follow us on Twitter , Telegram , and the BitMEX Blog . For further inquiries, please contact press@bitmex.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220102005033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom